Chih-Hsi Scott Kuo
Overview
Explore the profile of Chih-Hsi Scott Kuo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin T, Chang P, Lo C, Chuang H, Lee C, Chang C, et al.
Immun Inflamm Dis
. 2024 Nov;
12(11):e70065.
PMID: 39575691
Background: Eosinophil activation is associated with asthma. Whether air pollution affects the activation of blood eosinophils in patients with asthma remains unknown. In this study, we investigated the correlation between...
2.
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
Tung P, Chiu T, Huang A, Ju J, Huang C, Wang C, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231222604.
PMID: 38249338
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in -mutant...
3.
Hung L, Hsu P, Yang C, Kuo C, Chang J, Huang C, et al.
Aging (Albany NY)
. 2024 Jan;
16(1):550-567.
PMID: 38194721
Background: In real-world practice, most patients with lung cancer are diagnosed when they are aged ≥65 years. However, clinical trials tend to lack data for the elderly population. Therefore, we...
4.
Ju J, Huang A, Tung P, Huang C, Chiu T, Wang C, et al.
Sci Rep
. 2023 Nov;
13(1):20323.
PMID: 37989860
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR subtype and generation of...
5.
Lin C, Chou Y, Su P, Lin C, Chang J, Huang C, et al.
Am J Cancer Res
. 2023 Oct;
13(9):4208-4221.
PMID: 37818047
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the standard therapy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), treatment outcomes vary significantly. Previous studies have...
6.
Kuo C, Su P, Wei Y, Ko J, Tseng J, Su J, et al.
Am J Cancer Res
. 2023 Aug;
13(7):3100-3112.
PMID: 37559987
Real-world data regarding the T790M mutation rate after acquiring resistance to first-line combination therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and bevacizumab in patients with advanced non-small-cell lung...
7.
Wu C, Hsu P, Chang J, Chang C, Huang C, Yang C, et al.
Thorac Cancer
. 2023 Aug;
14(25):2548-2557.
PMID: 37525557
Background: This study aimed to comprehensively evaluate the efficacy and toxicity of afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and toxicity in patients with cancer....
8.
Chang J, Chang C, Huang C, Yang C, Kuo C, Fang Y, et al.
Thorac Cancer
. 2022 Dec;
14(4):348-356.
PMID: 36525509
Background: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard treatments for advanced non-small cell lung cancer (NSCLC) patients harboring the EGFR mutation. Patients experiencing intolerable adverse events (AEs) would...
9.
Chang J, Huang C, Fang Y, Chang C, Yang C, Kuo C, et al.
Thorac Cancer
. 2022 Nov;
14(1):12-23.
PMID: 36424878
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. This study aimed to evaluate the...
10.
Ko H, Shie S, Wang C, Chiu C, Wang C, Yang T, et al.
Front Immunol
. 2022 Nov;
13:1011092.
PMID: 36341427
Introduction: Uncommon epidermal growth factor receptor (EGFR) mutations include single and complex mutations. However, the association of the smoking status of patients with uncommon and complex mutations remains unclear. Methods:...